LUCID DIAGNOSTICS INC.(LUCD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

LUCD LUCID DIAGNOSTICS INC.

Trading 08-27 11:32:54 EDT

1.01

+0.03

+3.53%

High1.01	Low0.9600	Vol313.26K
Open0.9612	D1 Closing0.9707	Amplitude5.15%
Mkt Cap204.26M	Tradable Cap153.23M	Total Shares203.24M
T/O310.62K	T/O Rate0.21%	Tradable Shares152.47M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"LUCD","market":"US","secType":"STK","nameCN":"LUCID DIAGNOSTICS INC.","latestPrice":1.005,"timestamp":1787844742120,"preClose":0.9707,"halted":0,"volume":313255,"delay":0,"changeRate":0.03533532502317903,"floatShares":152466941,"shares":203244000,"eps":-0.461613,"marketStatus":"Trading","change":0.0343,"latestTime":"08-27 11:32:54 EDT","open":0.9612,"high":1.01,"low":0.96,"amount":310619.710987,"amplitude":0.051509,"askPrice":1.01,"askSize":963,"bidPrice":1,"bidSize":1268,"shortable":3,"etf":0,"ttmEps":-0.461613,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1787860800000},"marketStatusCode":2,"adr":0,"listingDate":1634184000000,"exchange":"NASDAQ","adjPreClose":0.9707,"preHourTrading":{"tag":"盘前","latestPrice":0.967,"preClose":0.9707,"latestTime":"09:29 EDT","volume":48467,"amount":46600.228549219995,"timestamp":1787837399018,"change":-0.0037,"changeRate":-0.003812,"amplitude":0.04028},"postHourTrading":{"tag":"盘后","latestPrice":0.9611,"preClose":0.9707,"latestTime":"19:58 EDT","volume":71868,"amount":70714.511347,"timestamp":1787788718351,"change":-0.0096,"changeRate":-0.00989,"amplitude":0.029772},"volumeRatio":1.246405},"requestUrl":"/m/hq/s/LUCD","defaultTab":"news","newsList":[{"id":"2659114436","title":"Lucid Diagnostics (LUCD) Receives a Buy from Maxim Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2659114436","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659114436?lang=en_us&edition=fundamental","pubTime":"2026-08-14 20:56","pubTimestamp":1786712174,"startTime":"0","endTime":"0","summary":"In a report released today, Anthony Vendetti from Maxim Group maintained a Buy rating on Lucid Diagnostics, with a price target of $2.00. According...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/lucid-diagnostics-lucd-receives-a-buy-from-maxim-group-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/lucid-diagnostics-lucd-receives-a-buy-from-maxim-group-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4555","BK4551","LCDL","BK4596","BK4099","LCIZ","LCID","BK4082","LUCD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659714620","title":"Press Release: PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2659714620","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659714620?lang=en_us&edition=fundamental","pubTime":"2026-08-14 20:00","pubTimestamp":1786708800,"startTime":"0","endTime":"0","summary":"-- Increased patient onboarding at OSU-The James as commercial phase. of strategic engagement accelerated and clinical rollout continued. -- Continued development of the implantable physiological monitor. toward an early 2027 FDA 510 submission, with design freeze. nearing completion and manufacturing test runs performing well in. preliminary verification and validation ahead of final clinical. -- Lucid Diagnostics announced second quarter 2026 financial results and key. -- Recognized $1.5 million in EsoGuard Esophageal DNA Test revenue. -- Secured first laboratory benefit manager coverage po","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","BK4232","R","PAVM","BK4022","LUCD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659157305","title":"Lucid Diagnostics Reports Q2 Growth Ahead of Medicare Decision","url":"https://stock-news.laohu8.com/highlight/detail?id=2659157305","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659157305?lang=en_us&edition=fundamental","pubTime":"2026-08-13 20:48","pubTimestamp":1786625333,"startTime":"0","endTime":"0","summary":"Lucid Diagnostics ( ($LUCD) ) just unveiled an update. On August 13, 2026, Lucid Diagnostics reported that second-quarter 2026 revenue rose to $1.5...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/lucid-diagnostics-reports-q2-growth-ahead-of-medicare-decision?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/lucid-diagnostics-reports-q2-growth-ahead-of-medicare-decision?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LCIZ","BK4551","BK4099","LNGR","BK4082","LUCD","LCID","LCDL","BK4555","BK4596"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659376154","title":"PAVmed Subsidiary Lucid Diagnostics Posts 2Q Revenue of USD 1.5 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2659376154","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659376154?lang=en_us&edition=fundamental","pubTime":"2026-08-13 20:09","pubTimestamp":1786622978,"startTime":"0","endTime":"0","summary":"PAVmed subsidiary Lucid Diagnostics posts 2Q revenue of USD 1.5 millionPAVmed subsidiary Lucid Diagnostics posted 2Q26 revenue of USD 1.5 million from its EsoGuard esophageal DNA test.Test volume reac","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDL6k2GHD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PAVM","BK4082","LUCD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659200151","title":"Press Release: Lucid Diagnostics Provides Business Update and Reports Second Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2659200151","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659200151?lang=en_us&edition=fundamental","pubTime":"2026-08-13 20:00","pubTimestamp":1786622400,"startTime":"0","endTime":"0","summary":"-- Processed 2,770 EsoGuard Esophageal DNA Tests in 2Q26.-- Secured a commercial coverage policy for EsoGuard from Concert, a. healthcare technology company recently acquired by Lyric that establishes. laboratory testing policies its client health plans can adopt. The policy. recognizes EsoGuard as medically necessary for patients meeting. established screening criteria and has already been adopted by multiple. -- Developed a health economic cost-effectiveness model evaluating EsoGuard. screening to support commercial payor engagement and coverage decisions,with preliminary results demonstrating improved clinical outcomes and. $1.5 million. Operating expenses were approximately $14.3 million, which","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4555","LCID","LUCD","BK4551","PAVM","BK4232","BK4082","LCDL","BK4099","BK4022","R","LCIZ","BK4596"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659868521","title":"Lucid Diagnostics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2659868521","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659868521?lang=en_us&edition=fundamental","pubTime":"2026-08-13 06:22","pubTimestamp":1786573365,"startTime":"0","endTime":"0","summary":"Lucid Diagnostics Inc reports results for the quarter ended June 30 - Earnings SummaryLucid Diagnostics IncLUCD.OQreported a quarterly adjusted loss of 8 cents per share for the quarter ended June 30,","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nL8N4492B3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PAVM","BK4082","LUCD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659531188","title":"Lucid Diagnostics Inc: Qtrly REV $1.5 Mln, EPS $-0.08 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2659531188","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659531188?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:37","pubTimestamp":1786567052,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nFWN44917X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","LUCD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659188849","title":"Lucid Diagnostics Q2 FY26 Revenue Rises 25% to USD 1.5 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2659188849","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659188849?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:32","pubTimestamp":1786566748,"startTime":"0","endTime":"0","summary":"Lucid Diagnostics Q2 FY26 revenue rises 25% to USD 1.5 millionLucid Diagnostics posted Q2 revenue of USD 1.5 million, up 25% from a year earlier.Sales and marketing expense climbed to USD 5.8 million ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nNDLmsHMy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PAVM","BK4082","LUCD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658957300","title":"Lucid Diagnostics Inc Expected to Post a Loss of 7 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2658957300","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658957300?lang=en_us&edition=fundamental","pubTime":"2026-08-11 06:10","pubTimestamp":1786399809,"startTime":"0","endTime":"0","summary":"Lucid Diagnostics Inc <LUCD.OQ> expected to post a loss of7cents a share - Earnings PreviewLucid Diagnostics IncLUCD.OQLUCD.Ois expected to  show a rise in quarterly revenue when it reports  results o","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nL8N44726I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LUCD","BK4082","PAVM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657176542","title":"PAVmed Unit Lucid Diagnostics Wins Concert Commercial Coverage Policy for EsoGuard Test","url":"https://stock-news.laohu8.com/highlight/detail?id=2657176542","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657176542?lang=en_us&edition=fundamental","pubTime":"2026-08-05 20:48","pubTimestamp":1785934132,"startTime":"0","endTime":"0","summary":"PAVmed unit Lucid Diagnostics wins Concert commercial coverage policy for EsoGuard testPAVmed subsidiary Lucid Diagnostics won a positive Concert commercial coverage policy for its EsoGuard esophageal","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nNDL3rXdRF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PAVM","BK4082","LUCD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657542190","title":"Lucid Diagnostics Secures Commercial Coverage Policy Spanning Multiple Health Plans for Its Esoguard® Esophageal DNA Test","url":"https://stock-news.laohu8.com/highlight/detail?id=2657542190","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657542190?lang=en_us&edition=fundamental","pubTime":"2026-08-05 20:47","pubTimestamp":1785934049,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nFWN4420X1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","LUCD","PAVM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656855690","title":"Lucid Diagnostics to Present at Needham, Canaccord Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2656855690","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656855690?lang=en_us&edition=fundamental","pubTime":"2026-08-04 20:37","pubTimestamp":1785847024,"startTime":"0","endTime":"0","summary":"Lucid Diagnostics to present at Needham, Canaccord investor conferencesLucid Diagnostics, a PAVmed subsidiary, scheduled management meetings at the Needham Virtual MedTech & Diagnostics 1x1 Conference","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nNDL9wVzL6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LUCD","BK4082","PAVM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656255666","title":"Lucid Diagnostics Management Participates in Canaccord Genuity Growth Conference Fireside Chat","url":"https://stock-news.laohu8.com/highlight/detail?id=2656255666","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656255666?lang=en_us&edition=fundamental","pubTime":"2026-08-04 20:32","pubTimestamp":1785846758,"startTime":"0","endTime":"0","summary":"Lucid Diagnostics management participates in Canaccord Genuity Growth Conference fireside chatLucid Diagnostics management will attend the Needham Virtual MedTech & Diagnostics 1x1 Conference for meet","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nNDL9hZq2N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PAVM","BK4082","LUCD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655774178","title":"Lucid Diagnostics Schedules Business Update Call to Discuss Q2 2026 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2655774178","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655774178?lang=en_us&edition=fundamental","pubTime":"2026-07-30 20:33","pubTimestamp":1785414787,"startTime":"0","endTime":"0","summary":"Lucid Diagnostics schedules business update call to discuss Q2 2026 resultsLucid Diagnostics scheduled a second-quarter 2026 business update conference call for Aug. 13, 2026 at 8:30 a.m. ET.Managemen","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nNDL7sbXV8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PAVM","LUCD","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646849073","title":"Lucid Diagnostics Shareholders Approve Stock Authorization Increase","url":"https://stock-news.laohu8.com/highlight/detail?id=2646849073","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646849073?lang=en_us&edition=fundamental","pubTime":"2026-06-25 05:32","pubTimestamp":1782336730,"startTime":"0","endTime":"0","summary":"Lucid Diagnostics ( ($LUCD) ) has provided an update. On June 24, 2026, Lucid Diagnostics Inc. held its annual meeting of stockholders, with approx...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/lucid-diagnostics-shareholders-approve-stock-authorization-increase?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/lucid-diagnostics-shareholders-approve-stock-authorization-increase?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4099","LCIZ","BK4596","LUCD","BK4555","BK4082","LCID","BK4551","LCDL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646849823","title":"Lucid Diagnostics Shareholders Approve Charter Amendment Raising Authorized Common Shares to 400 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2646849823","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646849823?lang=en_us&edition=fundamental","pubTime":"2026-06-25 05:01","pubTimestamp":1782334878,"startTime":"0","endTime":"0","summary":"Lucid Diagnostics shareholders approve charter amendment raising authorized common shares to 400 millionLucid Diagnostics held its annual shareholder meeting on June 24, 2026.Shareholders backed an am","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260624:nNDL3FrwyL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","LUCD","PAVM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637035499","title":"Lucid Diagnostics director Dennis Matheis acquires 245,000 common shares for $245,270.00","url":"https://stock-news.laohu8.com/highlight/detail?id=2637035499","media":"Reuters","labels":["shareholding","insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637035499?lang=en_us&edition=fundamental","pubTime":"2026-05-22 04:20","pubTimestamp":1779394856,"startTime":"0","endTime":"0","summary":"Lucid Diagnostics director Dennis Matheis bought 245,000 common shares at a weighted average price of $1.Holdings rose to 1,033,443 shares following the purchase.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lucid Diagnostics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 21, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nNDL8KFLjX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PAVM","BK4082","LUCD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635081240","title":"PAVmed Q1 FY26 net loss widens to $7 million; operating expenses rise to $8.1 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635081240","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635081240?lang=en_us&edition=fundamental","pubTime":"2026-05-15 20:03","pubTimestamp":1778846597,"startTime":"0","endTime":"0","summary":"PAVmed posted a GAAP net loss attributable to common stockholders of USD 7 million, or USD 4.42 per diluted share, while operating expenses increased to USD 8.1 million.Revenue rose to USD 22,000, while cash and cash equivalents climbed to USD 6.5 million as of March 31, 2026.Veris Health advanced development of its implantable physiological monitor toward a planned FDA 510 submission, with presubmission and testing activities expected to begin soon.Lucid Diagnostics recognized USD 1.3 million of EsoGuard revenue on 3,177 tests, while its underwritten common stock offering netted about USD 17 million in proceeds.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PAVmed Inc. published the original content used to generate this news brief v","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nNDLbyCcN6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","PAVM","LUCD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635081284","title":"Press Release: PAVmed Provides Business Update and Reports First Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2635081284","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635081284?lang=en_us&edition=fundamental","pubTime":"2026-05-15 20:00","pubTimestamp":1778846400,"startTime":"0","endTime":"0","summary":"Veris Health progressed commercial expansion and advanced implantable physiological monitor development toward FDA submission. Lucid Diagnostics continued building commercial momentum and strengthened its balance sheet ahead of key upcoming reimbursement milestones. PAVmed advanced its relaunched medical device portfolio; evaluation of additional acquisition opportunities ongoing. Conference call and webcast to be held today, May 15, at 8:30 AM EDT. NEW YORK, May 15, 2026 /PRNewswire/ -- PAVmed Inc.  , a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc.   and Veris Health Inc. , and reported financial results for the first quarter ended March 31, 2026.The webcast will take place on Friday, May 15, 2026, at 8:30 AM and is accessible in the investor relations section of the Company's website at pavmed.com.  Alternat","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","BK4232","LUCD","PAVM","R","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635712335","title":"Press Release: Lucid Diagnostics Provides Business Update and Reports First Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2635712335","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635712335?lang=en_us&edition=fundamental","pubTime":"2026-05-14 20:00","pubTimestamp":1778760000,"startTime":"0","endTime":"0","summary":"Processed 3,177 EsoGuard tests and recognized 1Q26 revenue of $1.3 million, ending quarter with $45 million in proforma cash and a runway that extends into 2027 and past upcoming reimbursement milestones. Conference call and webcast to be held today, May 14, at 8:30 AM EDT. NEW YORK, May 14, 2026 /PRNewswire/ -- Lucid Diagnostics Inc.   a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc.  , today provided a business update for the Company and reported financial results for the first quarter ended March 31, 2026.The webcast will take place on Thursday, May 14, 2026, at 8:30 AM and will be accessible in the investor relations section of the Company's website at luciddx.com. Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name \"Lucid Diagnostics Business Update\" to jo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4555","LCID","BK4022","LCIZ","LUCD","BK4551","BK4596","BK4082","BK4232","BK4099","LCDL","R"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.luciddx.com","stockEarnings":[{"period":"1week","weight":-0.0389},{"period":"1month","weight":0.0745},{"period":"3month","weight":-0.0755},{"period":"6month","weight":-0.3259},{"period":"1year","weight":-0.1774},{"period":"ytd","weight":-0.1094}],"compareEarnings":[{"period":"1week","weight":-0.0039},{"period":"1month","weight":0.0365},{"period":"3month","weight":0.0152},{"period":"6month","weight":0.1168},{"period":"1year","weight":0.1874},{"period":"ytd","weight":0.1234}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.035074},{"month":2,"riseRate":0.8,"avgChangeRate":0.165426},{"month":3,"riseRate":0.4,"avgChangeRate":-0.121674},{"month":4,"riseRate":0.4,"avgChangeRate":-0.088036},{"month":5,"riseRate":0.4,"avgChangeRate":0.027971},{"month":6,"riseRate":0.4,"avgChangeRate":-0.052518},{"month":7,"riseRate":0.4,"avgChangeRate":-0.01165},{"month":8,"riseRate":0.8,"avgChangeRate":0.049101},{"month":9,"riseRate":0.25,"avgChangeRate":-0.178841},{"month":10,"riseRate":1,"avgChangeRate":0.186111},{"month":11,"riseRate":0.4,"avgChangeRate":-0.040647},{"month":12,"riseRate":0.2,"avgChangeRate":-0.154424}],"exchange":"NASDAQ","name":"LUCID DIAGNOSTICS INC.","nameEN":"LUCID DIAGNOSTICS INC."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.48.0","shortVersion":"4.48.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"LUCID DIAGNOSTICS INC.(LUCD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest LUCID DIAGNOSTICS INC.(LUCD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"LUCID DIAGNOSTICS INC.,LUCD,LUCID DIAGNOSTICS INC.股票,LUCID DIAGNOSTICS INC.股票老虎,LUCID DIAGNOSTICS INC.股票老虎国际,LUCID DIAGNOSTICS INC.行情,LUCID DIAGNOSTICS INC.股票行情,LUCID DIAGNOSTICS INC.股价,LUCID DIAGNOSTICS INC.股市,LUCID DIAGNOSTICS INC.股票价格,LUCID DIAGNOSTICS INC.股票交易,LUCID DIAGNOSTICS INC.股票购买,LUCID DIAGNOSTICS INC.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"LUCID DIAGNOSTICS INC.(LUCD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest LUCID DIAGNOSTICS INC.(LUCD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}